CompletedPhase 2NCT02012088
Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- Principal Investigator
- Dr. Alejandro MartinUniversity of Salamanca
- Intervention
- RCOMP(drug)
- Enrollment
- 91 enrolled
- Eligibility
- 60 years · All sexes
- Timeline
- 2013 – 2021
Study locations (14)
- Hospital Universitario de Alava, Vitoria-Gasteiz, Alava, Spain
- Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragon, Spain
- Hospital de Cabueñes, Gijón, Asturas, Spain
- Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
- ICO- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain
- Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
- Hospital Universitario de Salamanca, Salamanca, Castille and León, Spain
- Hospital Clínico Universitario de Valladolid, Valladolid, Castille and León, Spain
- Hospital Fundación de Alcorcón, Alcorcón, Madrid, Spain
- Hospital del Mar, Barcelona, Spain
- Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Hospital Universitario Infanta Leonor, Madrid, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02012088 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.